Tenaya Therapeutics, Inc. (TNYA) research
Tenaya Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.56
- As of
Tenaya Therapeutics, Inc. (TNYA): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-05.
As of . Source: SEC EDGAR filings for TNYA. Method and limitations.
Share the TNYA intelligence card
See the full TNYA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TNYA on one page. Preview it with sample data, then open it live with a free account.
Preview the TNYA dossierActive signals for TNYA
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 71% of TNYA (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +567% to TNYA (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +15072% to TNYA (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 70% of TNYA (2026Q2)
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 186.9%, EPS $-0.20 vs $-0.0697 estimate
FREE, NO ACCOUNT
Every signal on TNYA, as it fires
You are seeing 5 of 9 signals recorded on TNYA since 2026-05-26.
The five above landed across 2 days. The other 4 were recorded on 3 other days. 5 of the 9 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TNYA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 87990A106 · 2026Q2 | $4.8M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 87990A106 · 2026Q2 | $3.4M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 87990A106 · 2026Q2 | $3.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 87990A106 · 2026Q2 | $281K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 87990A106 · 2026Q2 | $8K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TNYA
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TNYA against its peers
TNYA's return on equity of -73.5% ranks in the 64th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-10-31 and 2025-12-31.
| Metric | TNYA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 1.6M | n/a | 16 |
| Operating margin | n/a | -1329.4% | n/a | 11 |
| Net margin | n/a | -1834.5% | n/a | 11 |
| Return on equity | -73.5% | -91.7% | 64 | 17 |
Peers (21): SMNR, NRXP, ARMP, CRBU, SPRB, HURA, ENGN, INO, VTVT, FHTX, CRBP, UNCY, COYA, GNLX, CLLS, VANI, KRRO, LENZ, CBUS, HUMA, AARD. Left out: BETRF (period gap), SPRC (period gap), TLSA (period gap), RNA (no annual filing). Fiscal periods ending between 2025-10-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (TNYA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more TNYA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to TNYAand get the insider, 13F, options, and confluence read in one view.